GetTopicDetailResponse(id=0e6b11601ecd, topicName=epcoritamab, introduction=, content=濾泡性淋巴瘤 epcoritamab, image=null, comments=0, allHits=824, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Jun 29 00:22:22 CST 2024, time=2024-06-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=104072, tagList=[TagDto(tagId=104072, tagName=epcoritamab)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2275112, encodeId=255622e511213, content=<a href='/topic/show?id=82b0269997f' target=_blank style='color:#2F92EE;'>#侵襲性B細(xì)胞淋巴瘤#</a> <a href='/topic/show?id=0e6b11601ecd' target=_blank style='color:#2F92EE;'>#epcoritamab#</a>, objectTitle=【Blood】格菲妥單抗或epcoritamab治療侵襲性B細(xì)胞淋巴瘤的真實(shí)世界研究, objectType=article, longId=888534, objectId=ecbd8885347d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230705/1688571376675_5579292.jpg, objectUrl=/article/show_article.do?id=ecbd8885347d, replyNumber=0, likeNumber=17, createdTime=2025-07-28, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ecbd8885347d, moduleTitle=【Blood】格菲妥單抗或epcoritamab治療侵襲性B細(xì)胞淋巴瘤的真實(shí)世界研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ecbd8885347d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2251906, encodeId=0b4f2251906e3, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#彌漫性大B細(xì)胞淋巴瘤#</a> <a href='/topic/show?id=0e6b11601ecd' target=_blank style='color:#2F92EE;'>#epcoritamab#</a>, objectTitle=【Blood】Epcoritamab聯(lián)合GemOx治療不適合移植R/R DLBCL的EPCORE NHL-2研究結(jié)果, objectType=article, longId=863248, objectId=a0cf8632487b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250213/1739437670488_8538692.jpg, objectUrl=/article/show_article.do?id=a0cf8632487b, replyNumber=0, likeNumber=35, createdTime=2025-02-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=a0cf8632487b, moduleTitle=【Blood】Epcoritamab聯(lián)合GemOx治療不適合移植R/R DLBCL的EPCORE NHL-2研究結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a0cf8632487b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212258, encodeId=aeab2212258a1, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#濾泡性淋巴瘤#</a> <a href='/topic/show?id=0e6b11601ecd' target=_blank style='color:#2F92EE;'>#epcoritamab#</a>, objectTitle=【柳葉刀血液學(xué)】CD3/CD20雙抗Epcoritamab治療R/R FL的2期研究結(jié)果, objectType=article, longId=832164, objectId=1a5583216496, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719591134161_5579292.jpg, objectUrl=/article/show_article.do?id=1a5583216496, replyNumber=0, likeNumber=124, createdTime=2024-06-29, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1a5583216496, moduleTitle=【柳葉刀血液學(xué)】CD3/CD20雙抗Epcoritamab治療R/R FL的2期研究結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1a5583216496)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-06-29發(fā)表于上海
